
Americans Are Drinking Less Alcohol Than Ever Before. Here's What To Know
Gallup has been tracking trends in drinking behavior among Americans since 1939. The lowest percentage of alcohol consumption prior to this year was in 1958 when alcohol intake was reported at 55%.
For young Americans, the results are even more telling. Nearly 50% of Americans aged 18 to 34 reported drinking alcohol, compared to 56% of people 35 and up.
For the first time ever, the majority (53%) of Americans believe that moderate drinking (having one or two drinks a day) is unhealthy, demonstrating a major shift in the public perception of alcohol. These trends come as there has been increasing social awareness of the deleterious effects of alcohol on health.
As an example, major medical societies like the American Public Health Association have spoken out against the harmful effects of alcohol. The APHA has stated that alcohol has no health benefits. The World Health Organization has similarly stated that no amount of alcohol consumption is safe for health.
Alcohol can cause a series of health problems for individuals. The drug is associated with a number of cancers- including the breast, colon, liver, mouth and esophagus; to name a few. Long-term effects of alcohol can also lead to high blood pressure, heart disease, liver disease and a weakened immune system that can make individuals susceptible to getting infections.
The growing health concerns over alcohol could also be shifting cultural norms surrounding alcohol. For decades, alcohol has been celebrated in American culture and has been synonymous with parties, weddings and major sporting events. As the majority of Americans now believe moderate drinking is unhealthy, Americans may start to choose non-alcoholic alternatives in an effort to augment health.
Given these shifts, there may be strong support for public health messaging and warning labels on alcohol, such as those suggested by prior U.S. Surgeon General Vivek Murthy. Dr. Murthy has called for cancer warning labels on alcohol products, and this could serve as a tipping point towards wider reforms for alcohol, similar to how warning labels have been placed on tobacco cigarettes.
Despite the general trend of decreased alcohol consumption in the United States, many Americans still drink alcohol with a percentage rate of 54% still representing a majority. Over 140,000 Americans die from the effect of alcohol in an average year and one in ten Americans over the age of 12 suffer from Alcohol Use Disorder, according to the National Center for Drug Abuse Statistics. Much more work still needs to be done to ensure Americans remain healthy from the detrimental effects of alcohol.
The data from the July 2025 Gallup poll is clear- Americans are now drinking at historic lows and there is a growing awareness of the harms of even moderate alcohol consumption. If these trends are sustained, the public health benefits could be immense. Less alcohol intake would mean lower rates of cancer, cardiovascular disease, liver disease, and harm related to interpersonal violence and traffic accidents.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CNN
27 minutes ago
- CNN
On GPS: The Trump administration's war on science
Secretary of Health and Human Services Robert F. Kennedy Jr. announced that he is cutting nearly half a billion dollars in federally funded mRNA vaccine research. Fareed speaks with former Baltimore Health Commissioner Dr. Leana Wen about the promises of mRNA technology for treating infectious diseases and the impact of cuts on America's scientists.

Wall Street Journal
27 minutes ago
- Wall Street Journal
A Trump-Biden Mind Meld on Price Controls
Photo: Eric Thayer/Bloomberg News Your editorial 'The Political Race for Fewer Cures' (Aug. 6) identifies an ironclad rule of economics: Price controls create shortages. In this instance, restrictions on prescription drugs will lead to fewer cures. But there's another unintended consequence: Price controls will push down rebate payments to health plans. Those payments by drug makers are linked to list price—the higher the price, the higher the rebate payment. The sums allow patients to more easily access prescription drugs through lower out-of-pocket costs and reduced paperwork for doctors. Yet when the government artificially pushes down prices, they reduce rebate payments to health plans and their pharmacy benefit managers.
Yahoo
an hour ago
- Yahoo
1 Beaten-Down Stock That Could Soar by the End of the Year
Key Points Viking's leading weight management candidate is being investigated in two formulations. The stock could soar later this year, provided the oral version aces phase 2 studies. Viking Therapeutics is somewhat risky, but it also has significant upside potential. 10 stocks we like better than Viking Therapeutics › Some smaller drugmakers choose to develop medicines for diseases for which there are no therapeutic options. This allows them to avoid direct competition from larger pharmaceutical companies. That's not exactly the strategy Viking Therapeutics (NASDAQ: VKTX) chose. The mid-cap biotech is working on weight loss therapies, an increasingly competitive market dominated by Eli Lilly (NYSE: LLY) and Novo Nordisk, as well as numerous other well-established players in the industry seeking to enter the space. Going up against these giants is no small challenge, but Viking is, so far, holding its own. And if it can play its cards right, its stock could soar by the end of the year and go on to generate strong returns from then on out. Here's more on Viking Therapeutics. Eli Lilly's setback creates an opportunity Viking Therapeutics' shares soared last year following the release of strong phase 2 data for its subcutaneous weight management candidate, VK2735. The stock has declined significantly since that milestone, although it's not due to anything Viking did wrong. Broader market volatility, combined with long-term shareholders taking some profits, is likely responsible for the stock's 40% drop over the trailing-12-month period. VK2735 is currently in phase 3 studies, but Viking is also developing an oral version of the medicine, which is in phase 2 clinical trials. There is a race to develop a highly effective oral GLP-1 anti-obesity therapy, since the current market leaders are administered via subcutaneous injection. If Viking Therapeutics' oral candidate can impress in mid-stage studies, the stock could soar. That's especially the case since Eli Lilly's investigational oral GLP-1 medicine, orforglipron, failed to perform as well as expected in a phase 3 study in obese or overweight patients who didn't have diabetes. Orforglipron led to a mean weight loss of 12.4% in a 72-week study, which wasn't as impressive as the market wanted. This result paled in comparison to Lilly's injectable Zepbound, which led to an average weight loss of 20.2% in a phase 3 study. Viking Therapeutics' shares jumped on the pharmaceutical giant's bad news, but there's plenty of upside left if its oral weight loss candidate meets Wall Street's expectations. It's best to start small Eli Lilly is perceived as the leader in the weight management market. The company's continued dominance in this field was likely somewhat baked into investor expectations, requiring it to deliver outstanding clinical trial results to justify its share price. Viking is a much smaller drugmaker than Lilly, so the market will likely have lower expectations for its data readouts for VK2735. Viking also has several other exciting candidates. The company is working on a drug called VK2809, a potential therapy for metabolic dysfunction-associated steatohepatitis (MASH), which produced solid results in phase 2 studies. There is a vast unmet need in MASH, considering several million people have the disease, yet the U.S. Food and Drug Administration has approved just a single medication for it. Elsewhere, Viking has a next-gen anti-obesity candidate that could soon start human clinical trials. The company has a lot going on, and if VK2735-related developments remain strong through the end of the year, the stock could soar. However, Viking -- like any clinical-stage biotech company -- is a somewhat risky bet. On the one hand, it has generated strong mid-stage data for two separate medicines that address high unmet needs. Its leading candidate, VK2735, has the potential to become a blockbuster; that's impressive. Even so, the stock will plummet if VK2735 encounters clinical setbacks. So, should you buy shares? In my view, it depends on your level of risk tolerance. Risk-averse investors should look elsewhere. If you're comfortable with a bit of volatility, you should seriously consider the stock; however, it would be wise to start by initiating a small position. If the data from the ongoing phase 2 study for oral VK2735 is good, it might be worth adding even more shares thereafter. Should you buy stock in Viking Therapeutics right now? Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has positions in Eli Lilly, Novo Nordisk, and Viking Therapeutics. The Motley Fool recommends Novo Nordisk and Viking Therapeutics. The Motley Fool has a disclosure policy. 1 Beaten-Down Stock That Could Soar by the End of the Year was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data